EMAIL THIS PAGE TO A FRIEND

Veterinary microbiology

Nasal immunization with M cell-targeting ligand-conjugated ApxIIA toxin fragment induces protective immunity against Actinobacillus pleuropneumoniae infection in a murine model.


PMID 25818577

Abstract

Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia and severe economic loss in the swine industry has been caused by the infection. Therefore, the development of an effective vaccine against the bacteria is necessary. ApxII toxin, among several virulence factors expressed by the bacteria, is considered to be a promising vaccine candidate because ApxII toxin not only accompanies cytotoxic and hemolytic activities, but is also expressed in all 15 serotypes of bacteria except serotypes 10 and 14. In this study, we identified the peptide ligand capable of targeting the ligand-conjugated ApxIIA #5 fragment antigen to nasopharynx-associated lymphoid tissue. It was found that nasal immunization with ligand-conjugated ApxIIA #5 induced efficient mucosal and systemic immune responses measured at the levels of antigen-specific antibodies, cytokine-secreting cells after antigen exposure, and antigen-specific lymphocyte proliferation. More importantly, the nasal immunization induced protective immunity against nasal challenge infection of the bacteria, which was confirmed by histopathological studies and bacterial clearance after challenge infection. Collectively, we confirmed that the ligand capable of targeting the ligand-conjugated antigen to nasopharynx-associated lymphoid tissue can be used as an effective nasal vaccine adjuvant to induce protective immunity against A. pleuropneumoniae infection.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA010592
Anti-CD74 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1400110
Anti-GCNT2 antibody produced in mouse, IgG fraction of antiserum, buffered aqueous solution
HPA026776
Anti-GCNT2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1410519
Anti-GCNT2 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1407025
Anti-ST6GALNAC2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV53653
Anti-ST6GALNAC2 antibody produced in rabbit, affinity isolated antibody
SAB2701389
Anti-ST6GALNAC2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA048849
Anti-ST6GALNAC2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA031734
Anti-TAF8 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2106983
Anti-TAF8 antibody produced in rabbit, affinity isolated antibody
SAB1410223
Anti-TAF8 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1408305
Anti-TBN antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB2106801
Anti-TCN2 antibody produced in rabbit, affinity isolated antibody
SAB1406586
Anti-VIPR1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA026777
Anti-VIPR1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4503084
Anti-VIPR1, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB1402715
Monoclonal Anti-CD74 antibody produced in mouse, clone 1D1, purified immunoglobulin, buffered aqueous solution
SAB1402938
Monoclonal Anti-TCN2 antibody produced in mouse, clone 2F4, purified immunoglobulin, buffered aqueous solution